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Abstract 
Aims 
Following cardiac resynchronization therapy (CRT), atrioventricular (AV) optimization 
is not routinely practiced. To evaluate its clinical utility, we examined the effect of AV 
delay optimization on the prognostic biomarker N-terminal fragment pro-brain natriuretic 
peptide (NT-proBNP). 
Methods and Results  
We prospectively studied 72 patients (mean age73±12.5y, 70.8%male, 55.6%ischaemic) 
undergoing iterative AV optimization. Patients were divided into those whose nominal 
setting appeared ideal and not changed (Group 1, n=22) and those whose AV delay was 
optimized (Group 2, n=50). All patients underwent NT-proBNP assessment prior to CRT, 
pre- and a median 5 days post-optimization. Compared with Group 1, NT-proBNP fell 
significantly in Group 2 patients (median 474pg/ml) following optimization (p=0.00001). 
A significant change in filling pattern (defined as a change in AV delay>50ms) was 
required in 30% of patients, and it was this subgroup that derived the greater reduction in 
NT-proBNP levels(-1407pg/ml, IQR -3042 to -346pg/ml) compared to those requiring 
<50ms AV delay change(-125 pg/ml, IQR -1038 to 6 pg/ml), p=0.0011. The benefit of 
AV optimization was principally observed in reverse remodelling non-responders 
(median -2167pg/ml, IQR-3042 to -305pg/ml) and in patients with pseudonormal or 
restrictive filling pattern  (median -1407pg/ml, IQR-2809 to -342), compared with those 
with more benign diastolic filling (median – 264pg/ml, IQR -1038 to -21) p=0.033. 
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Conclusions  
In one-third of patients major filling pattern changes are achieved with AV optimization, 
associated with subsequent rapid falls in NT-proBNP. The greater the AV delay change, 
the larger the NT-proBNP fall, and non-responders and those with restrictive or 
pseudonormal filling despite CRT are most likely to benefit. 
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Introduction 
 
Following cardiac resynchronization therapy (CRT) the atrioventricular (AV) delay can 
be individually modified to maximally enhance ventricular filling and preload (AV delay 
optimization). The physiological argument for optimizing preload, particularly in heart 
failure (HF) patients with progressively increasing age (1-4), is clear and the acute 
haemodynamic benefits of achieving AV synchrony are well described (5,6). Notably the 
landmark CRT trials all included AV optimization as standard procedure (7-10). This has 
led to recent guidelines advocating the role of routine AV delay optimization following 
CRT (11). 
Despite this, AV delay optimization is rarely performed in clinical practice (12). The 
2006 ACT registry (3130 patients with St Jude devices at 213 USA centres) showed  
routine AV optimization to be  performed in only 6.3% of patients (13). This under-
utilization is likely related in part to logistical issues of coordinating the 
echocardiographic and pacing services and in part due to the many disparate techniques 
available to perform AV optimization. Concern also exists around the lack of robust short 
and long term evidence of the clinical benefits of AV optimization. In the recent 
SMART-AV trial, using improvement in left ventricular end-systolic volume at 6 months 
as the primary endpoint, the study demonstrated no significant difference between the 
fixed AV delay and either echo or EGM derived optimized AV delay (14). The dearth of 
evidence has led some centres to advocate the use of AV delay optimization only in 
patients judged to be nonresponders, despite there being no evidence to underpin this 
practice (14).     
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For CRT AV delay optimization to become more widely accepted there is still a real need 
to establish its clinical utility. Further, clarification is also required to identify whether 
AV delay optimization is worthwhile in all patients who undergo CRT or whether it 
should be reserved just for nonresponders to CRT. Therefore, using the iterative 
technique recommended by the American Society of Echocardiography (11), we assessed 
the impact of AV delay optimization on the powerful prognostic biomarker N-terminal 
fragment pro-B type natriuretic peptide levels (NT-proBNP) (15,16). By comparing two 
groups; those whose nominal setting appeared ideal and was not changed (Group 1), and 
those whose AV delay was optimized (Group 2). We hypothesized that a programmed 
optimal AV delay would cause an early rapid reduction (within one week) in the NT-
proBNP compared to patients not requiring programming of their AV delay.  
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Methods 
 
Study Population. All patients undergoing clinical CRT implantation in accordance with 
international guidelines (17) at St George’s Hospital between 2009 and 2010 were invited 
to take part in the study.  All patients were required to be more than 3 months post CRT 
and to demonstrate sinus rhythm, and to be optimised on stable heart failure (HF) 
medications. All patients had a fixed ‘out-of-the-box’ AV delay device setting following 
implantation. Patients were excluded from the study if a technically satisfactory 
echocardiogram could not be obtained.  
 
Study protocol. The clinical status (New York Heart Association HF classification-
NYHA) and left ventricle (LV) functional assessment by 2D-transthoracic 
echocardiography was assessed prior to CRT implantation and at the time of AV 
optimization.  Blood samples for measurement of NT-proBNP levels were also drawn at 
baseline (one day prior to CRT implantation), immediately prior to AV optimization and 
then within 1 week following AV optimization. The study conformed to the principles 
outlined in the Declaration of Helsinki and was approved by the local Research Ethics 
Committee. All patients provided written informed consent. 
 
Imaging 
 The echocardiographic images were recorded with a Vivid 7 ultrasound system 
(Vingmed Ultrasound AS, General Electric, Horten, Norway) equipped with a 2.5- to 5-
MHz imaging probe and off-line cine-loop analysis software. Measurements made 
included left ventricular ejection fraction (LVEF), LV dimensions/volumes, severity of 
 7 
mitral regurgitation (MR) and trans-mitral pulsed-wave (PW) Doppler derived diastolic 
parameters including the early diastolic (E) and atrial (A) wave velocities, the E/A ratio, 
the deceleration time (DT) of the E-wave and the annular septal tissue velocity (E’) . In 
our study the presence of mitral E/A ratio of <0.8 or DT >200ms was considered 
evidence of abnormal relaxation (IR). A pseudonormal (PN) was defined by the presence 
of mitral E/A of 0.8 to 1.5 and DT of 160 to 200ms, but distinguished from normal filling 
pattern by a septal E’ of <8cm/s.  Restrictive diastolic filling was defined as mitral 
E/A >2 or DT < 160ms. (18) 
 
AV Optimization 
The iterative method was used for the optimization of the AV delay (7,11). The technique 
involves observing the mitral PW Doppler LV filling waves as the AV delay is 
programmed long (240ms) and progressively decreased in 20ms steps until there is 
compromise of the left atrial contribution to LV filling (minimum AV delay 40ms). The 
AV delay is then increased in 10ms increments till there is no further A wave attenuation 
and the diastolic filling time has been maximised. This process takes approximately 15 to 
20 minutes. The interventricular delay was set at 0 ms (simultaneous LV and RV pacing). 
 
Plasma NT-proBNP measurements.  
Patients rested in the supine position for at least 15 min before blood sampling. All 
samples were analysed for NT-proBNP using an Immulite 2500 (Siemens Healthcare 
Diagnostics). The interassay coefficient of variation was 5.0% at 380 ng/L, 4.4 at 8700 
ng/L, 5.0% at 13000 ng/L, with detection limit 20 ng/L and upper measuring limit 35000 
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ng/L. All kits had the same lot number.  The normal NT-proBNP range of a healthy 
population is <125 pg/mL, Analysis of the samples was performed by an operator blinded 
to the results of the optimization process. 
 
Data Analysis  
For the purposes of data analysis patients were divided into 2 groups: Group 1-Patients 
who did not require alteration to their trans-mitral filling pattern. Group 2- Patients who 
required modification of their AV delay. Results are presented as mean ±1 standard 
deviation (SD) for continuous normally-distributed variables, as median [interquartile 
range] for continuous skewed distributed data, and as percentages for categorical data. 
Analysis of normality was performed with the Kolmogorov–Smirnov and Shapiro-Wilk 
test. Comparison of normally distributed continuous variables was performed using 
Student’s t test for paired and unpaired data. Non-normally distributed variables were 
compared using Mann-Whitney Rank Sum tests and Kruskal-Wallis tests. Comparison of 
categorical data was performed using Chi-square and Fisher's Exact Tests where 
appropriate. Linear regression analysis was calculated to evaluate the association between 
changes in AV delay and NT-proBNP. Using the median reduction of NT-proBNP 
observed in Group 2 (>474 pg/ml) as the cut off threshold, sensitivity, specificity, 
likelihood ratio, accuracy and p values were calculated individually at each tabulation 
(from 30ms up to 100ms change in AV delay). The best cut-off point corresponds to the 
AV delay change with the best likelihood ratio, highest accuracy, and the most significant 
p value. Statistical significance was established as p<0.05. All analyses were performed 
with SPSS statistical package for Windows (SPSS 17.0, Chicago, Illinois). 
 9 
Results 
 
Study Population 
One hundred and sixty three patients were considered for enrolment into the study. After 
meeting exclusion criteria (atrial fibrillation in 28 patients, medication change required in 
21 patients), 114 patients were considered for recruitment into the study. A further 33 
patients declined to consent and 9 patients were unable to attend for repeat blood test, 
leaving a final study population of 72.     
The baseline patient demographics and echocardiographic characteristics prior to CRT 
implantation and at the time of AV optimization are shown in Table 1. All study patients 
had LBBB morphology with QRS duration > 120ms. No patient had RBBB or 
nonspecific interventricuular conduction delay. The majority of patients were clinical 
responders (improvement by at least 1 NYHA classification from baseline) with 69.5 % 
found to be in NYHA class I or II functional class. Moreover, 35% (25/72) of patients 
demonstrated evidence of significant LV reverse remodelling post CRT, as defined by ≥ 
15% reduction in LV end systolic volume. With regard to lead positioning the LV lead 
was placed in a posterolateral (n=29), posterior (n=27), or lateral (n=16) cardiac vein. 
The right atrial lead was positioned in the right atrial appendage and the right ventricular 
lead was placed in the septum (n=53) or apex (n=19) of the right ventricle. AV delay 
optimization took place after a median 93 (IQR 79-111) days following CRT. Of the 72 
patients, 22 (30.5%) did not require change to their ‘box setting’ AV delay (Group 1). 
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Comparison of Groups.  
Pre-CRT. Both Group 1 and Group 2 had similar baseline demographics (Table 1). 
However, there was evidence of greater electrical dyssynchrony prior to CRT in Group 1 
(QRS duration 176 ± 29 ms versus 152 ± 26 ms, p=0.005) compared to Group 2. 
 
At the time of AV optimization. Both groups were observed to have a similar response 
to CRT, albeit with a trend towards more positive LV reverse remodelling in Group 1, 
with 45% of patients in Group 1 (with pre-existing optimal delay) showing evidence of ≥ 
15% reduction in LV end systolic volume compared to the 30% of patients requiring AV 
optimization (p=0.2). Patients in Group 2 were also observed to have more severe MR 
with 42% in Group 2 vs. 18.2% in Group 1 demonstrating evidence of MR grading 3 and 
4 (p=0.044). Group 2 patients also had correspondingly higher median NT-proBNP 
following CRT compared to Group 1 (Group 2: 2915 pg/ml (IQR 1386-8398 pg/ml) vs. 
Group 1: 1272 pg/ml (IQR 603-3246 pg/ml, p=0.022). 
 
Atrioventricular delay optimization 
The AV delay required alteration in 69% of patients (50/72) with the majority of these 
patients requiring atrial sense programming (66.7%). (The baseline and final median AV 
delay were 120ms and 100ms (IQR 60-170ms) respectively).  
There was an observed wide spectrum of change in the AV delay with a median change 
in AV delay of 50 ms from baseline (IQR 40 to 60 ms). (Figure 1)  
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Effect of AV delay programming on NT-proBNP 
Change in NT-proBNP. After a median 5 days (IQR 2-5) following AV optimization, 
the NT-proBNP significantly dropped by a median of 474 pg/ml (IQR -61 to -1822 pg/ml 
reduction, p=0.000005) following AV delay manipulation in Group 2. In comparison the 
NT-proBNP increased by a median 80 pg/ml (IQR -32 to +244 pg/ml, p=0.12) in Group 1 
after a median 5 days (IQ 5 to 7 days). (Figure 2) To verify that the significant difference 
between the groups was not simply a factor of the larger initial NT-proBNP in Group 2 
(which would be expected to result in larger absolute changes in NT-proBNP), we also 
examined percentage change. In the optimised Group 2 the mean percentage change in 
NT-proBNP following optimisation was a fall of 21% (mean fall of 1081ng/l) whereas in 
the non-optimised Group 1, the mean percentage change in NT-proBNP was a small rise 
of +7% (mean rise of 171ng/l, p= 0.0004). 
 
Relationship of AV programming and change in NT-pro BNP. 
An inverse regression equation was found to best-fit with the variation of change to the 
AV delay from baseline with NT-proBNP fall (Figure 3). The reduction in NT-proBNP 
observed in those patients requiring AV delay optimization yielded a median value of 
474 pg/ml. An adjustment of the AV delay of 50ms from baseline was found to have the 
highest accuracy in producing a NT-proBNP reduction of greater than 474 pg/ml. This 
was reached in 32% (23/72) of all study patients with an associated likelihood ratio for a 
reduction in NT-pro BNP (of > 474 pg/ml) of 2.21 with an accuracy of 0.76. (Figure 4) 
Moreover patients requiring AV delay change ≥ 50 ms showed a median fall in NT-
proBNP of 1407 pg/ml (IQR -3042 to -346 p/ml)) compared to a fall of 125 pg/ml (IQR -
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1038 to +6 pg/ml) (p=0.0011) observed in those patients with a ≤ 50 ms AV delay 
change. 
 
Effect of AV delay programming on NT-pro BNP in specific subgroups 
Responders versus Nonresponders. Absence of response to CRT at the time of AV 
optimization (in terms of LVESV reduction <15% and no improvement in NYHA class) 
was noted in 15/50 (30%) of the patients in Group 2, and it was this cohort who derived 
the most benefit following AV delay adjustment with a median drop in NT-proBNP of 
2167 pg/ml (-3042 to -305), with 73% showing a NT-proBNP reduction greater than 
median threshold observed in the study (474 pg/ml). Also, amongst patients who derived 
symptomatic benefit (improvement >1 NYHA class) but showed no evidence of 
significant LV reverse remodelling (n=20/50 40%) there was a modest reduction in the 
NT-proBNP following AV optimization (median -694.5 pg/ml (-1279 to -248)). In 
contrast, those patients who showed a positive response to CRT (n=15, 30%) as 
evidenced by positive reverse LV remodelling (>15% reduction in LVESV) appeared not 
to derive so much benefit with only a slight reduction seen in their median NT-proBNP (-
65.5 pg/ml (-262 to +25)).  Despite this, 3/15 patients (20%) from the responder cohort 
demonstrated a NT-proBNP reduction greater than 474 pg/ml after AV optimization. All 
three of these patients had required a change in AV delay >50ms. Furthermore, there was 
no significant difference in the magnitude of change in AV delay between CRT 
responders and nonresponders (p=0.22). 
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Doppler transmitral LV filling pattern.  At the time of the AV delay optimization, the 
majority of patients 54% (n=27) exhibited an IR diastolic filling pattern by Doppler 
echocardiography. A further 38% (n=19) patients showed PN or restrictive LV filling. 
Interestingly, those patients demonstrating a normal or IR pattern often required the AV 
delay to be reduced to prevent E/A fusion due to the prolonged relaxation time (median 
reduction in AV delay of 40ms IQR -58 to +38), whereas in patients with PN or 
restrictive filling, a longer AV delay was required (median increase in AV delay of 35ms 
IQR -43 to +65). Furthermore, it was the PN/restrictive group who showed a significantly 
more marked reduction in the NT-proBNP (median -1407 pg/ml, IQR -2809 to -342) 
following AV adjustment compared to those patients with less severe diastolic filling 
patterns (normal or IR) ( median – 264 pg/ml, IQR -1038 to -21) p=0.033 (Figure 5). 
 
Follow up LV remodeling data 
At a median follow up period of 121 days (IQR 91- 175), 34 out of the 50 patients in 
Group 2 had a follow up echocardiogram performed. When subgrouping patients with 
regard to the response in NT-proBNP change following AV optimization it was 
reassuring to note that there was a trend towards improved LV remodelling at follow up 
[although not statistically significant] in those patients with a > 474pg/ml fall in NT-
proBNP, despite clearly demonstrating evidence of worse LV function at the time of 
optimization compared to the group with less < 474pg/ml fall in NT-proBNP. (Table 2) 
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Discussion 
This is the first study to report the neurohormonal impact, as assessed by NT-proBNP, of 
iterative AV delay optimization on HF patients following CRT. In 70% of individuals, 
AV delay continued to be suboptimal 90 days post CRT implantation and subsequent 
modulation of the AV delay initiated a significant drop in NT-proBNP (median 474 
pg/ml) within a week following optimization compared with those patients not requiring 
AV optimization (p=0.00001). Furthermore, a significant change in filling pattern was 
required in 30% of patients, defined as a change in their AV delay of greater than 50 ms, 
and it was this subgroup that derived the greatest reduction in NT-proBNP levels (1407 
pg/ml (IQR -3042 to -346 pg/ml) compared to those patients requiring less than a 50 ms 
AV delay change (median reduction 125 pg/ml (IQR -1038 to 6 pg/ml) (p=0.0011).  
Moreover, the benefit of AV optimization as defined by the magnitude of reduction in 
NT-proBNP was principally observed in 2 categories of patients at the time of 
optimization: 
1-  Nonresponders to CRT with respect to reverse remodelling plus symptoms 
(defined as those patients who demonstrated ≤ 15% reduction in their LV end 
systolic volume). Seventy three percent of non-responders demonstrated a fall > 
474pg/ml in NT-proBNP post AV optimization. 
2- Severe heart failure with pseudonormal or restrictive filling pattern despite CRT. 
 
Physiological impact of AV optimization.  
 
Understanding the pathophysiology underpinning BNP synthesis and function provides a 
valuable insight into the possible mechanistic benefit seen in patients undergoing AV 
delay optimization. The natriuretic peptide hormones are produced as a consequence of 
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cardiac myocyte stretching due to increased intracavity pressures in both atria and 
ventricles. Thus an AV delay programmed too long can cause early LV filling (E wave) 
to coincide with atrial contraction (A wave), and consequently reduce diastolic filling. A 
long AV delay may also lead to diastolic MR in heart failure patients due to high LV end 
diastolic pressures and the hiatus between atrial contraction and subsequent ventricular 
contraction. Conversely, an over-short AV delay prevents completion of ventricular 
filling, because ventricular contraction closes the mitral valve, truncating or even 
obliterating the atrial filling ‘A’ wave. Thus normalization in the mechanical timing 
between the LA and LV contraction during AV optimization may lead to: 
-improved LV diastolic filling and corresponding reduction in left atrial (LA) pressures 
-subsequent enhanced LV systolic function 
-and reduced diastolic mitral regurgitation 
and may account for the reduction in the NT-proBNP observed in our study.  
Of note in atrial fibrillation patients with normal systolic function, there is an acute drop 
in natriuretic peptides (within 24 hours) following electrical cardioversion to sinus 
rhythm (19). The mechanism for this reduction in NT-proBNP is thought to be due to 
restoration of LA systole and thus alleviation of the elevated LA pressure and 
corresponding improvement in LV diastolic filling. Similarly a properly timed, effective 
atrial contraction after AV optimization may cause a similar drop in the LA mean 
pressure and may contribute to the reduction in NT-proBNP observed in our study, 
particularly in patients with elevated LV end diastolic pressures and left atrial pressures. 
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With maximization of the LV preload, studies have clearly shown that the addition of an 
optimal AV delay is associated with a clear haemodynamic benefit and improvement in 
systolic function. In PATH-CHF study cohort, Aurrichio et al were able to demonstrate 
that individualized AV delay manipulation lead to a significant (p<0.0001) acute increase 
in invasive LV systolic parameters including the systolic pulse pressure (+16%) and LV 
dp/dt (a preload dependent marker of LV contractility) by approximately 25% (5). 
Similarly, this was non-invasively shown by Jansen et al, who observed a +32 ± 21% 
increase in LV dp/dt (derived from the mitral regurgitant jet on echocardiography) 
following AV optimization (20). Although, an acute increase in LV dp/dt that does not 
necessarily translate into clinical benefits (21). 
  
Additional improvement in diastolic function has also been reported following AV delay 
intervention. In a retrospective 215 patient study,  9% patients showed improvement in ≥ 
1 diastolic function stage after undergoing AV optimization (Ritter or iterative method) 
(22). Stahlberg et al, by means of an indirect estimate of the left atrial end-diastolic 
pressure - derived from the estimated pulmonary artery diastolic pressure obtained from a 
sensor in the right ventricular outflow tract (Implantable Haemodynamic Monitor (IHM) 
Chronicle®, Medtronic Inc, USA) - were able to show lower LA derived pressures 
following AV optimization (21.9 ± 8.1 mmHg vs. 23 ± 7.7 mmHg respectively, p<0.05) 
(23). Recently, using a novel direct continuous invasive ambulatory LA monitoring 
system (HeartPOD™ ISL St Jude Medical) the optimal AV delay (also using the 
transmitral iterative method) clearly correlated with a reduction in the LA pressures and 
improved LA filling profile (24). 
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Who should undergo AV optimization? 
 
Some have advocated AV delay optimisation only in the ‘nonresponder’ group to CRT 
(14). To date there has been no published evidence to substantiate this position. Our data 
to some extent supports this viewpoint, in that the derived benefit from AV optimization 
appeared to have the greatest impact on those patients with worse systolic function at the 
time of optimization. However, leaving a suboptimal AV delay after an expensive device 
implant would seem counterintuitive, and 3 out of 15 responder patients (20%) showed a 
>474pg/ml improvement in NT-proBNP following AV optimization, indicating that even 
in the responder group, if the AV delay changes required are large, then a further 
improvement in BNP is seen, above that for CRT alone. Notably in our study the benefit 
of AV optimization was also observed in patients who improved their clinical status 
(NYHA class reduction ≥ 1) without evidence of positive reverse remodelling. Often it is 
this subgroup of symptom responders who are denied access to CRT optimization clinics.  
Furthermore, the entire concept of response to therapy is problematic.(25) Not only is 
there no agreed consensus on the definition of response but clinical improvement derived 
from NYHA can be biased by ‘placebo-related improvement’ and can account to 15-30% 
of patients labelled as clinical responders (26), thereby excluding potential nonresponders 
wrongly labelled as clinical responders.  
A clear benefit was also observed in those patients with moderate to severe diastolic LV 
impairment as evidenced by transmitral PW Doppler inflow patterns (PN and restrictive 
filling patterns) at the time of AV optimization. Our findings would concur with previous 
studies that have shown that increases in stroke volume (as measured by aortic VTI) are 
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greater in those patients with PN/Restrictive filling patterns compared to the IR group 
following AV optimization. (27)  
 
Clinical applications 
Although our data has demonstrated that AV optimization post CRT can produce a 
significant reduction in NT-proBNP, there is a more pronounced impact in patients 
deemed to be nonresponders to CRT. Nonresponse to CRT remains a major clinical 
concern and the profound fall in NT-proBNP observed in this cohort confirms the 
importance in obtaining an optimal AV delay post CRT. Moreover, there is a need for 
further evaluation in a larger prospective study to assess if AV delay manipulation can 
convert so-called nonresponders to responders as judged by symptoms and LV reverse 
remodeling.  
 
Study limitations  
 
Firstly, it is difficult to separate those effects due to CRT alone from those due to AV 
delay optimization on the trajectory fall observed in the NT-proBNP. However due to the 
rapid fall seen in the NT-proBNP over a median 5 day period following AV optimization, 
one can infer that AV delay manipulation was the main contributor to the reduction seen 
in the NT-proBNP.  Furthermore, the dose response relationship between fall in NT-
proBNP and extent of change in optimal AV delay supports causality. Secondly, the short 
term nature of our study does not provide information about the long term clinical 
outcome of AV optimization. However, the inclusion of NT-proBNP, a useful prognostic 
marker in HF patients, may provide some clues to the possible translation to long term 
prognosis. We did not perform ventriculoventricular (VV) optimization as randomised 
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trials have shown lack of benefit following VV optimisation (27, 28). Hence, we cannot 
exclude the impact that VV optimization may have had on our study results.  
 
 
 
 
Conclusion 
 
Routine post CRT AV optimization employing the iterative method results in changes to 
the AV delay in the majority patients. In almost one third of patients, major changes to 
filling pattern can be achieved, associated with a subsequent rapid, significant fall in NT-
proBNP. The greater the change needed in AV delay, the larger the fall in NT-proBNP 
and non-responders and those with severe heart failure and restrictive or pseudonormal 
filling despite CRT are most likely to benefit. 
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Figure legends 
 
Figure 1. Change made in AV delay (ms) during AV delay programming in the Group 2 
cohort (n=50). 
 
Figure 2. The effect of AV optimization on plasma NT-proBNP levels (pg/ml). 
 Comparative distribution of NT-proBNP levels pre and post AV optimization in Groups 
1 and 2 are illustrated.  Corresponding median NT-proBNP are presented as median 
values (interquartile range) for pre CRT, pre and post AV optimization. 
 
Figure 3. Inverse regression analyses correlating the change made in AV delay and the 
change observed in  NT-proBNP in the Group 2 cohort. [pre and post AV optimization] 
 
Figure 4. Sensitivity and specificity cut off assessment with an adjustment of the AV 
delay >50ms from baseline found to have the highest accuracy in producing a NT-pro 
BNP reduction of greater than 474 pg/ml. 
 
Figure 5. Effect of AV delay programming on plasma NT-proBNP sub-grouped on the 
basis of Doppler transmitral LV filling pattern.  [pre and post AV optimization] 
IR= impaired relaxation 
PN= pseudonormal 
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Figure 1  
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Figure 2      Group 1 
 
BNP pre CRT pre OPT p value  BNP pre OPT post OPT p value 
1st Q 1712 603   1st Q 603 734  
median 3517 1272 0.0009  median 1272 1578 0.12 
3rd Q 5603 3246   3rd Q 3246 3158  
 
      Group 2 
                                    
BNP pre CRT pre OPT p value  BNP pre OPT post OPT p value 
1st Q 2154 1386   1st Q 1386 1069  
median 5916 2915 0.000009  median 2915 2924 0.000005 
3rd Q 13317 8398   3rd Q 8398 5499  
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Figure 3   
 
 
 
 
                                                                                                        n = 50 
 
 
 
Best Fit Line = Inverse regression with 95% prediction intervals 
 
 
Equation R F df1 df2 Sig. Constant b1 
Inverse -0.445 11.64 1 47 0.0013 -2391 60604 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
Figure 4 
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AVD 
change 
(ms) n sensitivity specificity likelihood accuracy p value 
        ratio     
 30 24 0.96 0.17 1.15 0.57 0.19 
 40 24 0.96 0.25 1.28 0.61 0.049 
 50 23 0.92 0.58 2.21 0.76 0.0002 
 60 16 0.64 0.71 2.19 0.67 0.015 
 70 9 0.36 0.88 1.47 0.61 0.06 
 80 7 0.28 0.92 3.36 0.59 0.14 
 90 4 0.16 0.92 1.92 0.53 0.67 
 100 3 0.12 0.92 1.44 0.51 1.00 
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Figure 5 
 
 
 
 
 
 
Median                              -264 pg/ml                                     -1407 pg/ml            p=0.033    
change NTproBNP                
 
IQR                                   [-1038 to -21]                                 [-2809 to -342] 
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Table 1. Patient Characteristics including subgroup demographics  
Variable 
Baseline Patient 
Characteristics 
Total Study 
Population 
(N=72) 
Group 1 
No AVD change 
(N=22) 
Group 2  
AVD change  
(N=50) 
Global  
P Value 
Grp 1 vs. 2 
PRE CRT     
Male 51 (70.8%) 14 (63.6%) 37 (74.0%) 0.37 
Age (years) 73±12.5 72±9.7 74±13.5 0.16 
QRS (ms) 160±29 176±29 152±26 0.005 
PR interval (ms) 200(166-238) 198 (157-238) 200 (174-236) 0.53 
Non Ischemic 32 (44.4%)  8 (36.4%) 24 (48.0%) 0.15 
 
NYHA III 
 
50 (69.4%) 
   
19 (86.4%) 
  
31 (62.0%) 
 
 
NYHA IV 22 (30.6%)    3 (13.6%) 19 (38.0%) 0.039 
 
Diabetes 13 (18.1%)    5 (22.7%)   8 (16.0%) 0.52 
Hypertension 30 (41.7%)    8 (36.4%)    22 (44.0%) 0.54 
NT pro-BNP (pg/ml) 5105 (1750-11712) 3517 (1712-5603) 5916 (2154-13317) 0.072 
     
LVEDV (ml) 218±60 228±68 212±56 0.41 
LVESV (ml) 160±59 165±65 157±57 0.55 
EF (%) 29±7.6 28±8.6 29±7.1 0.86 
LV inflow pattern     
Normal/ IR 26 11 15 (30%)  
PN/ Restrictive 42 10 32 (54%) 0.19 
MR grading     
1-2 30 (41.7%) 10 (45.5%) 20 (40.0%)  
3-4 35 (48.6%) 10 (45.5%) 
 
25 (50.0%) 0.68 
POST CRT at the time 
of AV optimization 
    
Time to AV Opt (days) 93 (79-111) 99 (92-116) 91 (64-99) 0.027 
NYHA I 4 (5.56%) 2 (9.09%) 2 (4.0%)  
NYHA II 46 (63.9%) 16 (72.7%) 30 (60%) 0.26 
NYHA III 22 (30.6%) 4 (18.2%) 18 (36%)  
Creatinine ( umol/L) 112 (88-141) 117 (89-137) 109 (85-147) 0.80 
NT proBNP (pg/ml) 2302 (901-6275) 1272 (603-3246) 2915 (1386-8398) 0.022 
ACEI    62 (86.1%) 19 (86.4%) 43 (86.0%) 0.65 
Beta-Blockers 57 (79.2%)  19 (86.4%) 38 (76.0%) 0.48 
Diuretics 55 (76.4%)   18 (81.8%)    37(74.0%) 0.74 
Spironolactone 21 (29.2%)   7  (31.8%) 14  (28.0%) 0.77 
Digoxin 2 (2.78%)  1 (4.55%) 1 (2.0%) 0.53 
Amiodarone 11(15.3%)   3 (13.6%) 8  (16.0%) 1.00 
 
LVEDV (ml) 187±61 185±63 187±61 0.80 
LVESV (ml) 121±60 113±52 125±64  
EF (%) 39±12 40±11 37±12 0.17 
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Data are presented as the mean value±SD for continuous variables and number and 
percentage of patients for nominal data and median (25
th
-75
th
 percentile) for non-
parametric variables.  
CRT-P= cardiac resynchronization therapy- biventricular pacing only; ACEI= 
angiotensin converting enzyme inhibitor; EF= ejection fraction NYHA= New York Heart 
Association; LVEDV= left ventricular end diastolic volume; LVESV= left ventricular 
end systolic volume; IR= impaired relaxation; PN= pseudonormal. 
* Clinical responder defined as ≥ 1 reduction in NYHA class post CRT. 
 
Echo responder defined as patients exhibiting ≥ 15% reduction in LVESV post CRT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LV inflow pattern 
Normal/ IR 49 (68.1%) 19 (86.3%) 30 (60%)  
PN/ Restrictive 23 (31.9%) 3 (13.6%) 20 (40%) 0.08 
MR grading     
1-2 46 (63.9%) 18 (81.8%) 28 (56.0%)  
3-4 25 (34.7%) 4 (18.2%) 21 (42.0%) 0.044 
Clinical Responder* 52 (72.2%) 17 (77.3%) 35 (70.0%) 0.53 
Echo Responder  25 (34.7%) 10 (45.5%) 15 (30.0%) 0.20 
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Table 2. Comparison of echocardiography follow up data for patients with > 474pg/ml 
fall in NT-proBNP versus patients with <  474pg/ml fall in NT-proBNP post AV 
optimization. 
 
 
 
 > 474pg/ml fall in  
NT-proBNP n=17 
p <  474pg/ml fall in 
NT-proBNP n=17 
p 
 CRT Opt Follow up*  CRT Opt Follow up*  
       
LVED 6.4 (0.6) 6.4 (0.7) 1.0 5.7 (0.9) 5.7 (1.0) 0.69 
LVEDV 231 (46) 218 (55) 0.31 160 (51) 169 (50) 0.44 
LVES 5.6 (0.74) 5.4 (1.1) 0.26 4.5 (1.0) 4.3 (1.2) 0.17 
LVESV 168 (77) 163 (57) 0.74 96 (50) 93 (48) 0.67 
EF 30 (9) 
30 (25-35) 
33 (12) 
34 (25-40) 
0.16 38 (13) 
40 (25-50) 
45 (15) 
45 (30-57) 
0.05 
 
*Follow up median 120 days (IQR 91-175) post CRT optimization  
 
Data are presented as the mean value±SD for continuous variables and median (25
th
-75
th
 
percentile) for non-parametric variables.  
EF= ejection fraction LVEDV= left ventricular end diastolic volume; LVESV= left 
ventricular end systolic volume. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
